Novartis (NYSE: NVS) is paying $1.1 billion upfront to buy Myricx Bio, a London-based biotech with its U.S. presence based in ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

As climate change brings longer droughts, more frequent heat waves and increasingly unpredictable growing conditions to ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

China and Hong Kong stocks rose on Monday as signs emerged that investor enthusiasm for artificial intelligence was ...

Candel Therapeutics (CADL) shifts to late-stage oncology with CAN-2409 Phase III wins and BLA catalyst. Read here for a ...

Healthcare veteran Dr Douglas Williams discusses the impact of recent political upheaval in the US and the prospect of major ...

Cancer treatments remain the top research focus as Beijing’s drive to make biotech a strategic industry draws attention in ...

Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...

Parabilis Medicines is ambitious, but it has Regeneron on its side already.

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...